Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla Lines Up A Slate Of US Launches For FY23

As COVID-19 Antibody Cocktail Now Available In India

Executive Summary

Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.

You may also be interested in...



Generics Industry Fails To Match Last Year’s Growth In First Quarter

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

FDA Hands Lannett Goal Date On Generic Advair

Lannett continues to eye the potential launch of its partnered Advair generic next year, after the lucrative respiratory asset was accepted for filing by the FDA.

Coronavirus Update: Storage Boost For Pfizer/BioNTech, More Positive Data For Regeneron Antibody Cocktail

The approved fridge storage time for Pfizer and BioNTech's Comirnaty has been extended to a month, Regeneron's scores with low-dose REGEN-COV, an early win for GSK and CureVac's next-generation mRNA vaccine and more orders of the AstraZeneca vaccine benefits Oxford Biomedica's bank balance.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;